- Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024
- Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
- Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
- Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
- Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments
- Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
- New partnership aims to advance vaccine against MERS coronavirus
- Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
- Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
- Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer
More ▼
Key statistics
On Friday, Barinthus Biotherapeutics PLC (BRNS:NMQ) closed at 1.91, 16.46% above the 52 week low of 1.64 set on Sep 25, 2023.
52-week range
Open | 1.98 |
---|---|
High | 2.05 |
Low | 1.86 |
Bid | 0.784 |
Offer | 2.00 |
Previous close | 2.00 |
Average volume | 14.16k |
---|---|
Shares outstanding | 39.03m |
Free float | 37.22m |
P/E (TTM) | -- |
Market cap | 74.55m USD |
EPS (TTM) | -1.83 USD |
Data delayed at least 15 minutes, as of May 31 2024 20:59 BST.
More ▼